AR046795A1 - Derivados de 2-amino-pirimidinas - Google Patents

Derivados de 2-amino-pirimidinas

Info

Publication number
AR046795A1
AR046795A1 ARP040104906A ARP040104906A AR046795A1 AR 046795 A1 AR046795 A1 AR 046795A1 AR P040104906 A ARP040104906 A AR P040104906A AR P040104906 A ARP040104906 A AR P040104906A AR 046795 A1 AR046795 A1 AR 046795A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
amino
saturated
groups
Prior art date
Application number
ARP040104906A
Other languages
English (en)
Inventor
Clifford David Jones
Richard Luke
William Mccoull
Original Assignee
Schuckmann Alfred Von
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0330000A external-priority patent/GB0330000D0/en
Priority claimed from GB0416849A external-priority patent/GB0416849D0/en
Application filed by Schuckmann Alfred Von filed Critical Schuckmann Alfred Von
Publication of AR046795A1 publication Critical patent/AR046795A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a derivados de 2-amino-pirimidinas, composiciones farmacéuticas de dichos compuestos, uso de dichos compuesto como medicamentos y en la producción de un efecto anti-angiogénico en un animal de sangre caliente. Procesos para la preparación de dichos compuestos. Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1) donde: R1 y R2 se seleccionan independientemente entre H, alquilsulfonilo C1-6, fenil(CH2)u- donde u es 0, 1, 2, 3, 4, 5, o 6, alcanoilo C1- 6, alquilo C1-6, alcoxicarbonilo C1-6, C3-6cicloalquil(CH2)x- en donde x es 0, 1, 2, 3, 4, 5 o 6 , o un anillo heteroarilo de 5 o 6 miembros, o R1 y R2 junto con el átomo de N al cual se encuentran unidos representan un anillo heterocíclico de 3 a 7 miembros saturado o parcialmente saturado que contiene opcionalmente otro heteroátomo seleccionado entre N o O; donde los grupos: alquilo C1-6, alcanoilo C1-6 y cicloalquilo C3-6 se sustituyen opcionalmente con uno o más grupos seleccionados independientemente entre fluoro, hidroxi, alquilo C1-6, alcoxi C1-6, alcoxi C1-6-alcoxi C1-6, alcoxi-C1-6-alcoxi C1-6-alcoxi C1-6, amino, mono(C1-6)alquilamino, di-[(C1-6)alquil]amino, carbamoilo, mono(C1-6)alquilcarbamoilo, di[(C1- 6)alquil]carbamoilo, N(Rd)C(O)(C1-6)alquilo en donde Rd es H o alquilo C1-6, un anillo heterocíclico de 3 a 7 miembros saturado o parcialmente saturado, o un anillo heteroarilo de 5 o 6 miembros, donde los grupos alcoxi C1-6, alcoxi C1-6-alcoxi C1- 6, alcoxi-C1-6-alcoxi C1-6-alcoxi C1-6, y los grupos alquilo C1-6 de los grupos mono(C1-6)alquilamino, di-[(C1-6)alquil]amino, mono(C1-6)alquilcarbamoilo, di[(C1-6)alquil]carbamoilo, y/o N(Rd)C(O)(C1-6)alquilo se sustituyen opcionalmente con uno o más grupos hidroxi; donde el fenilo se sustituye opcionalmente con uno o más grupos seleccionados independientemente entre halo, alquilo C1-6, alcoxi C1-6, amino, mono(C1-6)alquilamino, o di-[(C1-6)alquil]amino, donde los grupos alquilo C1-6 y alcoxi C1-6 se sustituyen opcionalmente con uno o más grupos seleccionados independientemente entre hidroxi, amino, mono(C1-6)alquilamino, o di-[(C1-6)alquil]amino, y donde cualquier anillo heterocíclico y heteroarilo en R1 y/o R2 se sustituye opcionalmente independientemente con uno o más de los siguientes alquilo C1-4, alcoxi C1-4, alcoxi C1-4-alquilo C1-4, hidroxi, amino, mono(C1-6)alquilamino, di-[(C1-6)alquil]amino, un anillo heterocíclico de 3 a 7 miembros saturado o parcialmente saturado o -C(O)(CH2)zY donde z es 0, 1, 2 o 3 y Y se selecciona entre H, hidroxi, alcoxi C1-4, amino, mono(C1-6)alquilamino, di-[(C1-6)alquil]amino o un anillo heterocíclico de 3 a 7 miembros saturado o parcialmente saturado; y con la condición de que cuando R1 y/o R2 es un grupo alcanoilo C1, luego el alcanoilo C1 no se sustituye con fluoro o hidroxi; R3 y R4 se seleccionan independientemente entre H, alquilo C1-6 o alcoxi C1-6, donde los grupos alquilo C1-6 y alcoxi C1-6 se sustituyen opcionalmente con uno o más grupos seleccionados independientemente entre fluoro, hidroxi, alquilo C1-6, alcoxi C1-6, amino, mono(C1-6)alquilamino, di-[(C1-6)alquil]amino, carbamoilo, mono(C1-6)alquilcarbamoilo o di[(C1-6)alquil]carbamoilo, un anillo heterocíclico de 3 a 7 miembros saturado o parcialmente saturado o un anillo heteroarilo de 5 o 6 miembros donde dichos anillos heterocíclicos y heteroarilo se sustituyen opcionalmente independientemente con uno o más de los siguientes alquilo C1-4, alcoxi C1-4, hidroxi, amino, mono(C1-6)alquilamino o di-[(C1-6)alquil]amino o un anillo heterocíclico de 3 a 7 miembros saturado o parcialmente saturado; o uno de R3 y R4 es como se define precedentemente y el otro representa un grupo - NR1R2 como se define precedentemente; A representa un grupo arilo o un anillo heteroarilo de 5 a 6 miembros seleccionados entre furilo, pirrolilo, tienilo, oxazolilo, isoxazolilo, imidazolilo, pirazolilo, tiazolilo, isotiazolilo, oxadiazolilo, tiadiazolilo, triazolilo, tetrazolilo, piridilo, piridazinilo, pirimidinilo, pirazinilo o 1,3,5-triazonilo; R5 se selecciona entre ciclopropilo, ciano, halo alcoxi C1-6 o alquilo C1-6, donde los grupos alquilo C1-6 y alcoxi C1-6 se sustituyen opcionalmente con ciano o con uno o más fluoro; n es 0, 1, 2 o 3; L se encuentra unido meta o para en el anillo A respecto del punto de unión del grupo etinilo y representa -C(RaRbC(O)N(R9)-, -N(R8)C(O)(RaRb)-, -N(R8)C(O)N(R9)-, -N(R8)C(O)O-, o - OC(O)-N(R)-, donde R8 y R9 representan independientemente H o alquilo C1-6 y donde Ra y Rb representan independientemente H o alquilo C1-6 o Ra y Rb junto con el átomo de C al cual se encuentran unidos representan cicloalquilo C3-6; B representa un anillo cicloalquilo C3-7, un anillo heterocíclico de 3 a 7 miembros saturado o parcialmente saturado, un grupo arilo, un anillo heteroarilo de 5 o 6 miembros seleccionado entre furilo, pirrolilo, tienilo, oxazolilo, isoxazolilo, imidazolilo, pirazolilo, tiazolilo, isotiazolilo, oxadiazolilo, tiadiazolilo, triazolilo, tetrazolilo, piridilo, piridazinilo, pirimidinilo, pirazinilo o 1,3,5-triazonilo, o un grupo bicíclico de 8, 9 o 10 miembros el cual contiene opcionalmente 1, 2, 3 o 4 heteroátomos seleccionados, independientemente entre N, O y S y el cual es saturado, parcialmente saturado o aromático; R6 se selecciona entre halo, ciano, oxo, un anillo cicloalquilo C3-7, un anillo heterocíclico de 3 a 7 miembros saturado o parcialmente saturado, y -N(Rc)C(O)(C1-6)alquilo en donde Rc es H o alquilo C1-6; o R6 se selecciona entre alquilo C1-6, -S(O)p-alquilo C1-6 donde p es 0, 1 o 2; o alcoxi C1-6, donde los grupos alquilo C1-6, -S(O)p-alquilo C1-6 y alcoxi C1-6 se sustituyen opcionalmente con uno o más grupos seleccionados independientemente entre ciano, fluoro, hidroxi, alcoxi C1-6, amino, mono(C1-6)alquilamino, di-[(C1-6)alquil]amino, un anillo cicloalquilo C3-7 o un anillo heterocíclico de 3 a 7 miembros saturado o parcialmente saturado; y donde el anillo cicloalquilo C3-7 y anillo heterocíclico de 3 a 7 miembros saturado o parcialmente saturado se sustituyen opcionalmente independientemente con uno o más grupos seleccionados entre alquilo C1-6; y m es 0, 1, 2 o 3; y cuando B es un anillo cicloalquilo C3-7, un anillo heterocíclico de 3 a 7 miembros saturado o parcialmente saturado o un grupo bicíclico de 8, 9 o 10 miembros saturado o parcialmente saturado, los anillos y el grupo bicíclico llevan opcionalmente 1 o 2 sustituyentes oxo o tioxo; y sales, prodrogas o solvatos del mismo.
ARP040104906A 2003-12-24 2004-12-27 Derivados de 2-amino-pirimidinas AR046795A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0330000A GB0330000D0 (en) 2003-12-24 2003-12-24 Compounds
GB0416849A GB0416849D0 (en) 2004-07-29 2004-07-29 Compounds

Publications (1)

Publication Number Publication Date
AR046795A1 true AR046795A1 (es) 2005-12-21

Family

ID=34712715

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104906A AR046795A1 (es) 2003-12-24 2004-12-27 Derivados de 2-amino-pirimidinas

Country Status (11)

Country Link
US (1) US20080108608A1 (es)
EP (1) EP1737463B1 (es)
JP (1) JP2007517007A (es)
AR (1) AR046795A1 (es)
AT (1) ATE415970T1 (es)
DE (1) DE602004018193D1 (es)
ES (1) ES2317079T3 (es)
HK (1) HK1102425A1 (es)
TW (1) TW200526597A (es)
UY (1) UY28701A1 (es)
WO (1) WO2005060970A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776869B2 (en) * 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
WO2006082371A1 (en) * 2005-02-01 2006-08-10 Astrazeneca Ab Pyrimidine compounds having tie2 (tek) inhibitory activity
US20100048543A1 (en) * 2005-02-01 2010-02-25 Astrazeneca Ab Pyrimidine compounds having ties (tek) inhibitory activity
GB0502418D0 (en) * 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
WO2006103449A2 (en) * 2005-03-31 2006-10-05 Astrazeneca Ab Saminopyrimidine derivates with tie2 inhibiting activity
ES2761180T3 (es) 2005-12-23 2020-05-19 Ariad Pharma Inc Compuestos bicíclicos de heteroarilo
CN103467385B (zh) * 2006-05-08 2016-03-09 阿里亚德医药股份有限公司 单环杂芳基化合物
JP5273037B2 (ja) 2006-05-08 2013-08-28 アリアド・ファーマシューティカルズ・インコーポレイテッド アセチレン性ヘテロアリール化合物
US8558002B2 (en) * 2006-11-16 2013-10-15 Allergan, Inc. Sulfoximines as kinase inhibitors
EP2070929A1 (en) * 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
US8846664B2 (en) 2008-11-12 2014-09-30 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
BRPI0915267A2 (pt) * 2008-11-14 2015-08-18 Concert Pharmaceuticals Inc Composto, composição farmacêutica livre de pirogênio, e, método de tratamento de uma doença ou uma condição
US9045453B2 (en) 2008-11-14 2015-06-02 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
EP2922838B1 (en) 2012-10-22 2018-03-14 Concert Pharmaceuticals Inc. Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} .
CA3022250A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
US10065934B2 (en) 2014-07-17 2018-09-04 Sunshine Lake Pharma Co., Ltd. Substituted urea derivatives and pharmaceutical uses thereof
WO2019011264A1 (en) * 2017-07-13 2019-01-17 Sunshine Lake Pharma Co., Ltd. SUBSTITUTED UREA DERIVATIVE SALT AND USE THEREOF IN MEDICINE
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5154728B2 (ja) * 2000-07-24 2013-02-27 クレニツキー・ファーマシューティカルズ，インコーポレイテッド 神経栄養活性を有する置換５−アルキニルピリミジン
DE60228103D1 (de) * 2001-10-02 2008-09-18 Smithkline Beecham Corp Chemische verbindungen
US20030225273A1 (en) * 2002-03-21 2003-12-04 Michaelides Michael R. Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
ES2309591T3 (es) * 2003-12-24 2008-12-16 Astrazeneca Ab Pirimidinas con actividad tie2(tek).

Also Published As

Publication number Publication date
DE602004018193D1 (de) 2009-01-15
EP1737463A1 (en) 2007-01-03
TW200526597A (en) 2005-08-16
UY28701A1 (es) 2005-07-29
ATE415970T1 (de) 2008-12-15
ES2317079T3 (es) 2009-04-16
JP2007517007A (ja) 2007-06-28
WO2005060970A1 (en) 2005-07-07
EP1737463B1 (en) 2008-12-03
HK1102425A1 (en) 2007-11-23
US20080108608A1 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
AR046795A1 (es) Derivados de 2-amino-pirimidinas
AR046996A1 (es) Derivados de amino-pirimidinas
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
AR038000A1 (es) Compuesto derivado de tien[2,3-d]pirimidin-2,4(1h,3h)-diona, composicion farmaceutica, proceso para su preparacion y su uso en la fabricacion de un medicamento
AR059687A1 (es) Derivados de pirazol inhibidores de la enzima mao-b,utiles para mejorar la funcion cognitiva, composiciones farmaceuticas que los contienen,y metodo de preparacion.
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR057072A1 (es) Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR054481A1 (es) Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
AR045510A1 (es) Derivados de 1,3 diazoles
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR059064A1 (es) Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer.
AR061815A1 (es) Compuesto de oxo-prolinamida composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
AR066659A1 (es) Derivados de espiroindolinona
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
AR063912A1 (es) Derivados de 1,2,4 oxadiazol. composiciones farmaceuticas.
AR053232A1 (es) Derivados de piridina condensadas, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de agentes terapeuticos antiinflamatorios y para el tratamiento de enfermedades relacionadas con el sistema inmunologico.
AR074238A1 (es) Compuesto de n-{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4,1.0]hept-4-il]metil}-2-heteroarilamina, su uso para la preparacion de un medicamento util para el tratamiento de una enfermedad que requiere un antagonista del receptor de orexina humano y composicion farmaceutica que lo comprende
AR039648A1 (es) Compuestos de aril cetona pirrolo triazina utiles como inhibidores de cinasa y las composiciones farmaceuticas que las contienen
AR056785A1 (es) COMPUESTOS DE IMIDAZO[1,2-A]PIRAZINAS, uTILES COMO INHIBIDORES, REGULADORES O MODULADORES DE PROTEINQUINASAS
AR069509A1 (es) Pirido (3,2-e) pirazinas, su procedimiento de preparacion y uso como inhibidores de fosfodiesterasa 10
RU2016135922A (ru) Терапевтические соединения и композиции

Legal Events

Date Code Title Description
FB Suspension of granting procedure